← Back to patent-cliff list
BL-0020
Tier C — Watch / tradeBL-0020
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TOP1
Indications (approved)：Small cell lung cancer, 三阴性乳腺癌, Pancreatic cancer, Solid tumour
Regional status
US
-
EU
-
China
Phase II
2026-02-13
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BL-0020?
Approved indications include: Small cell lung cancer, 三阴性乳腺癌, Pancreatic cancer, Solid tumour.
When does the BL-0020 patent expire?
No public expiry year is available for BL-0020 yet; this page updates once verified.
How do I get a quote for BL-0020 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29